Fangqiu Fu1,2,3, Yang Zhang1,2,3, Zhendong Gao1,2,3, Yue Zhao1,2,3, Zhexu Wen1,2,3, Han Han1,2,3, Yuan Li2,3,4, Hong Hu1,2,3, Haiquan Chen5,6,7. 1. Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. 2. Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China. 3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 5. Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai, 200032, China. hqchen1@yahoo.com. 6. Institute of Thoracic Oncology, Fudan University, Shanghai, 200032, China. hqchen1@yahoo.com. 7. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. hqchen1@yahoo.com.
Abstract
OBJECTIVE: Recent studies have indicated that CD47, interacting with SIRP-α, conveys "don't eat me" signal in evasion of tumor cells and serves as a potential target for cancer immunotherapy. The purpose of this study was to investigate the clinical correlation of CD47 and uncover prognostic implications of CD47 and CD68 in non-small cell lung cancer (NSCLC). METHODS: The specimens from 384 patients with completely resected NSCLC were collected for immunohistochemical assays of CD47 and CD68. Cox multivariate proportion hazard analyses were conducted to confirm the independent prognostic value of CD47 and CD68. TCGA database and GSE37745 were used to identify the association between CD47 and immune cells. RESULTS: In 186 pairs of lung cancer and adjacent tissues, the RNA of CD47 was overexpressed in lung cancer tissues (P < 0.001). High expression of CD47 was associated with worse recurrence-free survival in RNA and protein level (P = 0.032 and P < 0.001, respectively). High expression of CD47 was significantly associated with large tumor size (P = 0.004), advanced pathologic TNM stage (P < 0.001), and histology (P = 0.003). Further analyses demonstrated that CD47 and CD68 predicted outcomes of patients independently. In addition, the expression of CD47 correlated with neutrophils, and did not correlated with B cells and CD4 + T cells in the TCGA database and GSE37745. CONCLUSION: Combined use of CD47 and CD68 exhibited excellent performance in predicting survival of patients with NSCLC. CD47 was a potential therapeutic target for immune therapy of lung cancer.
OBJECTIVE: Recent studies have indicated that CD47, interacting with SIRP-α, conveys "don't eat me" signal in evasion of tumor cells and serves as a potential target for cancer immunotherapy. The purpose of this study was to investigate the clinical correlation of CD47 and uncover prognostic implications of CD47 and CD68 in non-small cell lung cancer (NSCLC). METHODS: The specimens from 384 patients with completely resected NSCLC were collected for immunohistochemical assays of CD47 and CD68. Cox multivariate proportion hazard analyses were conducted to confirm the independent prognostic value of CD47 and CD68. TCGA database and GSE37745 were used to identify the association between CD47 and immune cells. RESULTS: In 186 pairs of lung cancer and adjacent tissues, the RNA of CD47 was overexpressed in lung cancer tissues (P < 0.001). High expression of CD47 was associated with worse recurrence-free survival in RNA and protein level (P = 0.032 and P < 0.001, respectively). High expression of CD47 was significantly associated with large tumor size (P = 0.004), advanced pathologic TNM stage (P < 0.001), and histology (P = 0.003). Further analyses demonstrated that CD47 and CD68 predicted outcomes of patients independently. In addition, the expression of CD47 correlated with neutrophils, and did not correlated with B cells and CD4 + T cells in the TCGA database and GSE37745. CONCLUSION: Combined use of CD47 and CD68 exhibited excellent performance in predicting survival of patients with NSCLC. CD47 was a potential therapeutic target for immune therapy of lung cancer.
Authors: Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti Journal: Cell Date: 2010-09-03 Impact factor: 41.582
Authors: Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Keith Syson Chan; Inigo Espinosa; Mark Chao; David Wong; Laurie Ailles; Max Diehn; Harcharan Gill; Joseph Presti; Howard Y Chang; Matt van de Rijn; Linda Shortliffe; Irving L Weissman Journal: Proc Natl Acad Sci U S A Date: 2009-08-04 Impact factor: 11.205
Authors: Badreddin Edris; Kipp Weiskopf; Anne K Volkmer; Jens-Peter Volkmer; Stephen B Willingham; Humberto Contreras-Trujillo; Jie Liu; Ravindra Majeti; Robert B West; Jonathan A Fletcher; Andrew H Beck; Irving L Weissman; Matt van de Rijn Journal: Proc Natl Acad Sci U S A Date: 2012-03-26 Impact factor: 11.205
Authors: Johan Botling; Karolina Edlund; Miriam Lohr; Birte Hellwig; Lars Holmberg; Mats Lambe; Anders Berglund; Simon Ekman; Michael Bergqvist; Fredrik Pontén; André König; Oswaldo Fernandes; Mats Karlsson; Gisela Helenius; Christina Karlsson; Jörg Rahnenführer; Jan G Hengstler; Patrick Micke Journal: Clin Cancer Res Date: 2012-10-02 Impact factor: 12.531
Authors: Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon Journal: Immunity Date: 2013-10-17 Impact factor: 31.745
Authors: Lourdes Barrera; Edgar Montes-Servín; Juan-Manuel Hernandez-Martinez; María de Los Ángeles García-Vicente; Elizabeth Montes-Servín; Marytere Herrera-Martínez; José C Crispín; José Rafael Borbolla-Escoboza; Oscar Arrieta Journal: Br J Cancer Date: 2017-06-20 Impact factor: 7.640